Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual Meeting

Investigational roflumilast cream 0.05% met the primary endpoint and all secondary endpoints, showing significant improvement across multiple efficacy endpoints as early as Week 139.4% of children...

Related Keywords

San Diego ,California ,United States ,American ,Amanda Sheldon ,Derek Cole ,Latha Vairavan ,Drug Administration ,Nasdaq ,Exchange Commission ,Investor Relations Advisory Solutions ,Head Of Corporate Communications ,American Academy Of Dermatology ,Facebook ,Arcutis Biotherapeutics Inc ,Eczema Area ,Severity Index ,Worst Itch Numeric Scale ,Investigator Global Assessment ,Atopic Dermatitis ,American Academy ,Prescription Drug User Fee Act ,Private Securities Litigation Reform Act ,Vice President ,